Maxcyte revenues rise 21%, hailing three new strategic licences with cell therapy developers
Proactive Research analyst Emma Ulker discusses MaxCyte s (LON:MXCT) commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US $26.2mln in fiscal (FY) 2020.
Ulker says this included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in recurring revenues from instrument leases and disposable sales in cell therapy, accelerated by the receipt of milestone payments from partners.
Phát Huy Giá Trị Chiến Thắng 30-4-1975 Trong Sự Nghiệp Xây Dựng Quân Đội, Củng Cố Quốc Phòng, Bảo Vệ Tổ Quốc Thời Kỳ Mới
tin247.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tin247.com Daily Mail and Mail on Sunday newspapers.
Phát huy giá trị Chiến thắng 30-4-1975 trong sự nghiệp xây dựng quân đội, củng cố quốc phòng, bảo vệ Tổ quốc thời kỳ mới
qdnd.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from qdnd.vn Daily Mail and Mail on Sunday newspapers.